



### **Professor Massimo Pinzani, MD, PhD, FRCP, FAASLD, MAE**

Massimo Pinzani is a clinical and translational hepatologist, Emeritus Professor of Medicine at University College London (UCL), United Kingdom. He was Sheila Sherlock Chair of Hepatology and Director of the UCL Institute for Liver and Digestive Health, Division of Medicine from 2012 to 2023.

Professor Pinzani is one of the pioneers in the research dedicated to cellular and molecular mechanisms of liver fibrosis and relative diagnostic and therapeutic approaches. Current research is centred on regenerative medicine and on the development of extracellular matrix scaffold of liver, pancreas and small intestine for cell bioengineering and 3D disease modelling. Professor Pinzani research activity is summarised in 315 original peer-reviewed publications (H Index of 114, Scopus). He has served in the governing and scientific boards of major international organization in Hepatology and Gastroenterology, and as Editor in Chief and Associate Editor of top peer reviewed international journals in Gastroenterology and Hepatology. He served as Educational Chair from 2014 to 2019 and is currently Treasurer Elect of the European Association for the Study of the Liver (EASL). He is co-founder of Engitix Therapeutics Ltd, an UCL spin-off company dedicated to extracellular matrix-based drug discovery for tissue fibrosis and cancer in the liver and digestive system.

From February 2024, Professor Pinzani is the Scientific Director of UPMC (University of Pittsburgh Medical Center)-ISMETT in Palermo, Italy.